Screening for neuroblastoma in France: Methodological aspects and preliminary observations
✍ Scribed by Chauvin, F.; Mathieu, P.; Frappaz, D.; Lasset, C.; Favrot, M.C.; Greffe, J.; Esteve, J.; Thiesse, P.; Combaret, V.; Chauvot, P.; Boschetti, R.; David, L.; Brunat-Mentigny, M.; Philip, T.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 92 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
A pilot study of neuroblastoma mass screen-screening (one stage I, three stage II, one stage ing was initiated in January 1990 in the Rho ˆne III, three stage IVs). All are alive and well but French district. The expected number of births were good prognosis cases according to the per year is 26,000. The study is designed for a main prognostic factors. Five patients were dis-5-year period with three major goals: 1) mea-covered before screening (so called Halo effect): surement of the compliance rate of a voluntary one stage I, one stage III, three stage IVs. One test at 4 months of age; 2) evaluation of the died of disease and four are alive in complete technical value of high-pressure liquid chroma-remission after treatment. Two patients were tography (HPLC) as a screening method; and 3) false negative (one stage III with N-myc amplifidetailed biological characterization of all de-cation, one stage IV with bad prognosis features) tected tumors. and three cases of neuroblastoma were missed 61,551 children were screened between May because of noncompliance with the screening 1, 1990 and December 31, 1993. Participation program. was 69% in 1990, 81.5% in 1991, and over This pilot study concludes on the feasibility 83% in 1992.
of a mass screening program in France. The esti-HPLC was a satisfactory assay method. The mated cumulative incidence of neuroblastoma number of clinical examinations required for at 3 years is 1 per 4,375 living births and overdipositive tests as defined in the protocol is 1 agnosis is probable. All the detected cases were per 3,621 tests. The false positive rate is 1 per of good prognosis and the false negative ones 3,583 tests.
were poor prognosis cases. Med. Pediatr.